Hypersensitivity reactions to aspirin were described as early as 1902 but it was not until 1922 that Widal et al. first described the correlation between aspirin sensitivity, asthma, and nasal polyposis. Subsequently, in 1968, Samter and Beer described the full clinical characteristics of aspirin sensitivity and elucidated the classic triad of symptoms, eponymously named Samter’s Triad. Samter’s Triad is defined as chronic rhinosinusitis with nasal polyposis (CRSwNP), bronchial asthma, and reactions to aspirin or cyclooxygenase-1 (COX-1) inhibitors. Since its first description by Widal, there has been considerable literature published on the epidemiology, pathophysiology, and treatment of what is now termed aspirin-exacerbated respiratory disease (AERD).
Non-IgE hypersensitivity reaction to ASA/COX-1 inhibitors that is commonly comorbid with but not due to underlying allergic disease.
Characterized by marked eosinophilic inflammation and ongoing mast-cell activation in the respiratory mucosa.
Chronic rhinosinusitis with nasal polyposis (CRSwNP)
Reactions to aspirin/cyclooxygenase-1 (COX-1) inhibitors